ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antisense Oligonucleotides (ASO) Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-11J17453
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024
BUY CHAPTERS

Global Antisense Oligonucleotides (ASO) Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-11J17453
Report
October 2025
Pages:107
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Ionis Pharmaceuticals
Biogen
SOBI
Nippon Shinyaku
Jazz Pharmaceuticals

Antisense Oligonucleotides (ASO) Therapy Market Size

The global Antisense Oligonucleotides (ASO) Therapy market is projected to grow from US$ 4026 million in 2024 to US$ 12140 million by 2031, at a CAGR of 17.3% (2025-2031), driven by critical product segments and diverse end‑use applications.

Antisense Oligonucleotides (ASO) Therapy Market

Antisense Oligonucleotides (ASO) Therapy Market

Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases
From a downstream perspective, Neuromuscular Diseases accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Antisense Oligonucleotides (ASO) Therapy leading manufacturers including Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals, etc., dominate supply; the top five capture approximately % of global revenue, with Ionis Pharmaceuticals leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Antisense Oligonucleotides (ASO) Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Antisense Oligonucleotides (ASO) Therapy Market Report

Report Metric Details
Report Name Antisense Oligonucleotides (ASO) Therapy Market
Accounted market size in 2024 US$ 4026 million
Forecasted market size in 2031 US$ 12140 million
CAGR 17.3%
Base Year 2024
Forecasted years 2025 - 2031
Segment by Type
  • Intrathecal Injection
  • Intravenous Injections
  • Other
Segment by Application
  • Neuromuscular Diseases
  • hATTR
  • Other
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Antisense Oligonucleotides (ASO) Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

How fast is Antisense Oligonucleotides (ASO) Therapy Market growing?

Ans: The Antisense Oligonucleotides (ASO) Therapy Market witnessing a CAGR of 17.3% during the forecast period 2025-2031.

What is the Antisense Oligonucleotides (ASO) Therapy Market size in 2031?

Ans: The Antisense Oligonucleotides (ASO) Therapy Market size in 2031 will be US$ 12140 million.

Who are the main players in the Antisense Oligonucleotides (ASO) Therapy Market report?

Ans: The main players in the Antisense Oligonucleotides (ASO) Therapy Market are Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals

What are the Application segmentation covered in the Antisense Oligonucleotides (ASO) Therapy Market report?

Ans: The Applications covered in the Antisense Oligonucleotides (ASO) Therapy Market report are Neuromuscular Diseases, hATTR, Other

What are the Type segmentation covered in the Antisense Oligonucleotides (ASO) Therapy Market report?

Ans: The Types covered in the Antisense Oligonucleotides (ASO) Therapy Market report are Intrathecal Injection, Intravenous Injections, Other

1 Study Coverage
1.1 Introduction to Antisense Oligonucleotides (ASO) Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Antisense Oligonucleotides (ASO) Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Intrathecal Injection
1.2.3 Intravenous Injections
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global Antisense Oligonucleotides (ASO) Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Neuromuscular Diseases
1.3.3 hATTR
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antisense Oligonucleotides (ASO) Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Antisense Oligonucleotides (ASO) Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Antisense Oligonucleotides (ASO) Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Antisense Oligonucleotides (ASO) Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Intrathecal Injection Market Size by Players
3.3.2 Intravenous Injections Market Size by Players
3.3.3 Other Market Size by Players
3.4 Global Antisense Oligonucleotides (ASO) Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Antisense Oligonucleotides (ASO) Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Antisense Oligonucleotides (ASO) Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Antisense Oligonucleotides (ASO) Therapy Market Size by Type (2020-2031)
6.4 North America Antisense Oligonucleotides (ASO) Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Antisense Oligonucleotides (ASO) Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Antisense Oligonucleotides (ASO) Therapy Market Size by Type (2020-2031)
7.4 Europe Antisense Oligonucleotides (ASO) Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Antisense Oligonucleotides (ASO) Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Antisense Oligonucleotides (ASO) Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Antisense Oligonucleotides (ASO) Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Antisense Oligonucleotides (ASO) Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Antisense Oligonucleotides (ASO) Therapy Market Size by Type (2020-2031)
9.4 Central and South America Antisense Oligonucleotides (ASO) Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Antisense Oligonucleotides (ASO) Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Antisense Oligonucleotides (ASO) Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Antisense Oligonucleotides (ASO) Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Antisense Oligonucleotides (ASO) Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Corporation Information
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Product Features and Attributes
11.1.4 Ionis Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Ionis Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Revenue by Product in 2024
11.1.6 Ionis Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Revenue by Application in 2024
11.1.7 Ionis Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Revenue by Geographic Area in 2024
11.1.8 Ionis Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
11.1.9 Ionis Pharmaceuticals Recent Developments
11.2 Biogen
11.2.1 Biogen Corporation Information
11.2.2 Biogen Business Overview
11.2.3 Biogen Antisense Oligonucleotides (ASO) Therapy Product Features and Attributes
11.2.4 Biogen Antisense Oligonucleotides (ASO) Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Biogen Antisense Oligonucleotides (ASO) Therapy Revenue by Product in 2024
11.2.6 Biogen Antisense Oligonucleotides (ASO) Therapy Revenue by Application in 2024
11.2.7 Biogen Antisense Oligonucleotides (ASO) Therapy Revenue by Geographic Area in 2024
11.2.8 Biogen Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
11.2.9 Biogen Recent Developments
11.3 Sobi
11.3.1 Sobi Corporation Information
11.3.2 Sobi Business Overview
11.3.3 Sobi Antisense Oligonucleotides (ASO) Therapy Product Features and Attributes
11.3.4 Sobi Antisense Oligonucleotides (ASO) Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Sobi Antisense Oligonucleotides (ASO) Therapy Revenue by Product in 2024
11.3.6 Sobi Antisense Oligonucleotides (ASO) Therapy Revenue by Application in 2024
11.3.7 Sobi Antisense Oligonucleotides (ASO) Therapy Revenue by Geographic Area in 2024
11.3.8 Sobi Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
11.3.9 Sobi Recent Developments
11.4 Nippon Shinyaku
11.4.1 Nippon Shinyaku Corporation Information
11.4.2 Nippon Shinyaku Business Overview
11.4.3 Nippon Shinyaku Antisense Oligonucleotides (ASO) Therapy Product Features and Attributes
11.4.4 Nippon Shinyaku Antisense Oligonucleotides (ASO) Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Nippon Shinyaku Antisense Oligonucleotides (ASO) Therapy Revenue by Product in 2024
11.4.6 Nippon Shinyaku Antisense Oligonucleotides (ASO) Therapy Revenue by Application in 2024
11.4.7 Nippon Shinyaku Antisense Oligonucleotides (ASO) Therapy Revenue by Geographic Area in 2024
11.4.8 Nippon Shinyaku Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
11.4.9 Nippon Shinyaku Recent Developments
11.5 Jazz Pharmaceuticals
11.5.1 Jazz Pharmaceuticals Corporation Information
11.5.2 Jazz Pharmaceuticals Business Overview
11.5.3 Jazz Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Product Features and Attributes
11.5.4 Jazz Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Jazz Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Revenue by Product in 2024
11.5.6 Jazz Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Revenue by Application in 2024
11.5.7 Jazz Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy Revenue by Geographic Area in 2024
11.5.8 Jazz Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
11.5.9 Jazz Pharmaceuticals Recent Developments
12 Antisense Oligonucleotides (ASO) TherapyIndustry Chain Analysis
12.1 Antisense Oligonucleotides (ASO) Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Antisense Oligonucleotides (ASO) Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Antisense Oligonucleotides (ASO) Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Ionis Pharmaceuticals
Biogen
SOBI
Nippon Shinyaku
Jazz Pharmaceuticals
List of Tables
 Table 1. Global Antisense Oligonucleotides (ASO) Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Antisense Oligonucleotides (ASO) Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Antisense Oligonucleotides (ASO) Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Antisense Oligonucleotides (ASO) Therapy Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Antisense Oligonucleotides (ASO) Therapy Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Antisense Oligonucleotides (ASO) Therapy Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Antisense Oligonucleotides (ASO) Therapy Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Antisense Oligonucleotides (ASO) Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotides (ASO) Therapy as of 2024)
 Table 11. Global Antisense Oligonucleotides (ASO) Therapy Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Antisense Oligonucleotides (ASO) Therapy Companies Headquarters
 Table 13. Global Antisense Oligonucleotides (ASO) Therapy Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Antisense Oligonucleotides (ASO) Therapy Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Antisense Oligonucleotides (ASO) Therapy Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Antisense Oligonucleotides (ASO) Therapy Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Antisense Oligonucleotides (ASO) Therapy Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Antisense Oligonucleotides (ASO) Therapy High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Antisense Oligonucleotides (ASO) Therapy Growth Accelerators and Market Barriers
 Table 25. North America Antisense Oligonucleotides (ASO) Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Antisense Oligonucleotides (ASO) Therapy Growth Accelerators and Market Barriers
 Table 27. Europe Antisense Oligonucleotides (ASO) Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Antisense Oligonucleotides (ASO) Therapy Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Antisense Oligonucleotides (ASO) Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Antisense Oligonucleotides (ASO) Therapy Investment Opportunities and Key Challenges
 Table 31. Central and South America Antisense Oligonucleotides (ASO) Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Antisense Oligonucleotides (ASO) Therapy Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Antisense Oligonucleotides (ASO) Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Ionis Pharmaceuticals Corporation Information
 Table 35. Ionis Pharmaceuticals Description and Major Businesses
 Table 36. Ionis Pharmaceuticals Product Features and Attributes
 Table 37. Ionis Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Ionis Pharmaceuticals Revenue Proportion by Product in 2024
 Table 39. Ionis Pharmaceuticals Revenue Proportion by Application in 2024
 Table 40. Ionis Pharmaceuticals Revenue Proportion by Geographic Area in 2024
 Table 41. Ionis Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
 Table 42. Ionis Pharmaceuticals Recent Developments
 Table 43. Biogen Corporation Information
 Table 44. Biogen Description and Major Businesses
 Table 45. Biogen Product Features and Attributes
 Table 46. Biogen Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Biogen Revenue Proportion by Product in 2024
 Table 48. Biogen Revenue Proportion by Application in 2024
 Table 49. Biogen Revenue Proportion by Geographic Area in 2024
 Table 50. Biogen Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
 Table 51. Biogen Recent Developments
 Table 52. Sobi Corporation Information
 Table 53. Sobi Description and Major Businesses
 Table 54. Sobi Product Features and Attributes
 Table 55. Sobi Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Sobi Revenue Proportion by Product in 2024
 Table 57. Sobi Revenue Proportion by Application in 2024
 Table 58. Sobi Revenue Proportion by Geographic Area in 2024
 Table 59. Sobi Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
 Table 60. Sobi Recent Developments
 Table 61. Nippon Shinyaku Corporation Information
 Table 62. Nippon Shinyaku Description and Major Businesses
 Table 63. Nippon Shinyaku Product Features and Attributes
 Table 64. Nippon Shinyaku Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Nippon Shinyaku Revenue Proportion by Product in 2024
 Table 66. Nippon Shinyaku Revenue Proportion by Application in 2024
 Table 67. Nippon Shinyaku Revenue Proportion by Geographic Area in 2024
 Table 68. Nippon Shinyaku Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
 Table 69. Nippon Shinyaku Recent Developments
 Table 70. Jazz Pharmaceuticals Corporation Information
 Table 71. Jazz Pharmaceuticals Description and Major Businesses
 Table 72. Jazz Pharmaceuticals Product Features and Attributes
 Table 73. Jazz Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Jazz Pharmaceuticals Revenue Proportion by Product in 2024
 Table 75. Jazz Pharmaceuticals Revenue Proportion by Application in 2024
 Table 76. Jazz Pharmaceuticals Revenue Proportion by Geographic Area in 2024
 Table 77. Jazz Pharmaceuticals Antisense Oligonucleotides (ASO) Therapy SWOT Analysis
 Table 78. Jazz Pharmaceuticals Recent Developments
 Table 79. Raw Materials Key Suppliers
 Table 80. Distributors List
 Table 81. Market Trends and Market Evolution
 Table 82. Market Drivers and Opportunities
 Table 83. Market Challenges, Risks, and Restraints
 Table 84. Research Programs/Design for This Report
 Table 85. Key Data Information from Secondary Sources
 Table 86. Key Data Information from Primary Sources


List of Figures
 Figure 1. Antisense Oligonucleotides (ASO) Therapy Product Picture
 Figure 2. Global Antisense Oligonucleotides (ASO) Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Intrathecal Injection Product Picture
 Figure 4. Intravenous Injections Product Picture
 Figure 5. Other Product Picture
 Figure 6. Global Antisense Oligonucleotides (ASO) Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Neuromuscular Diseases
 Figure 8. hATTR
 Figure 9. Other
 Figure 10. Antisense Oligonucleotides (ASO) Therapy Report Years Considered
 Figure 11. Global Antisense Oligonucleotides (ASO) Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Antisense Oligonucleotides (ASO) Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Antisense Oligonucleotides (ASO) Therapy Revenue Market Share by Region (2020-2031)
 Figure 15. Global Antisense Oligonucleotides (ASO) Therapy Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. Intrathecal Injection Revenue Market Share by Player in 2024
 Figure 18. Intravenous Injections Revenue Market Share by Player in 2024
 Figure 19. Other Revenue Market Share by Player in 2024
 Figure 20. Global Antisense Oligonucleotides (ASO) Therapy Revenue Market Share by Type (2020-2031)
 Figure 21. Global Antisense Oligonucleotides (ASO) Therapy Revenue Market Share by Application (2020-2031)
 Figure 22. North America Antisense Oligonucleotides (ASO) Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 23. North America Top 5 Players Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) in 2024
 Figure 24. North America Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Type (2020 - 2031)
 Figure 25. North America Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 26. US Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 27. Canada Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 28. Mexico Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 29. Europe Antisense Oligonucleotides (ASO) Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. Europe Top 5 Players Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) in 2024
 Figure 31. Europe Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 32. Europe Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 33. Germany Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 34. France Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 35. U.K. Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 36. Italy Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 37. Russia Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Antisense Oligonucleotides (ASO) Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Top 8 Players Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) in 2024
 Figure 40. Asia-Pacific Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Asia-Pacific Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Indonesia Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 43. Japan Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 44. South Korea Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 45. Australia Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 46. India Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 47. Indonesia Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 48. Vietnam Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 49. Malaysia Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 50. Philippines Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 51. Singapore Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2031) & (US$ Million)
 Figure 52. Central and South America Antisense Oligonucleotides (ASO) Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 53. Central and South America Top 5 Players Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) in 2024
 Figure 54. Central and South America Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 55. Central and South America Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Brazil Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2025) & (US$ Million)
 Figure 57. Argentina Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2025) & (US$ Million)
 Figure 58. Middle East and Africa Antisense Oligonucleotides (ASO) Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 59. Middle East and Africa Top 5 Players Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) in 2024
 Figure 60. South America Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 61. Middle East and Africa Antisense Oligonucleotides (ASO) Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 62. GCC Countries Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2025) & (US$ Million)
 Figure 63. Israel Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2025) & (US$ Million)
 Figure 64. Egypt Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2025) & (US$ Million)
 Figure 65. South Africa Antisense Oligonucleotides (ASO) Therapy Revenue (2020-2025) & (US$ Million)
 Figure 66. Antisense Oligonucleotides (ASO) Therapy Industry Chain Mapping
 Figure 67. Channels of Distribution (Direct Vs Distribution)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024
Global ASO based Drug Market Research Report 2024
Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024
Global Antisense ODN Market Research Report 2024
Global Antisense Oligonucleotides Market Research Report 2024
Global Antisense Oligonucleotides ASO Drug Market Research Report 2024
Global Antisense Oligonucleotides ASOs Drugs Market Research Report 2024
Global Antisense Oligonucleotide Service Market Research Report 2025
Global Antisense oligonucleotides ASO Drug and siRNA Drug Market Research Report 2024
Antisense Oligonucleotide ASO Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Nucleic Acid Drugs Market Research Report 2025
Global Antisense Oligonucleotides Drugs for ATTR Market Research Report 2024
Antisense and RNAi Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oligonucleotide Therapeutics Market Research Report 2024
Global CNS Specific Antisense Oligonucleotides Market Research Report 2024
Global Oligonucleotide Drugs ONs Market Research Report 2025
Global Oligonucleotide Oligo Drugs Market Research Report 2024
Antisense and RNAi Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oligonucleotide Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Low Molecular Weight Nucleic Acid Drugs Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions